ATE437878T1 - Metallchelate von makrocyclischen polyaminocarbonsäurederivaten und deren anwendung bei der diagnostischen bilderzeugung - Google Patents

Metallchelate von makrocyclischen polyaminocarbonsäurederivaten und deren anwendung bei der diagnostischen bilderzeugung

Info

Publication number
ATE437878T1
ATE437878T1 AT06725304T AT06725304T ATE437878T1 AT E437878 T1 ATE437878 T1 AT E437878T1 AT 06725304 T AT06725304 T AT 06725304T AT 06725304 T AT06725304 T AT 06725304T AT E437878 T1 ATE437878 T1 AT E437878T1
Authority
AT
Austria
Prior art keywords
diagnostic imaging
polyaminocarbonic
macrocyclic
application
acid derivatives
Prior art date
Application number
AT06725304T
Other languages
English (en)
Inventor
Marc Port
Original Assignee
Guerbet Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guerbet Sa filed Critical Guerbet Sa
Application granted granted Critical
Publication of ATE437878T1 publication Critical patent/ATE437878T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1854—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly(meth)acrylate, polyacrylamide, polyvinylpyrrolidone, polyvinylalcohol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT06725304T 2005-03-24 2006-03-24 Metallchelate von makrocyclischen polyaminocarbonsäurederivaten und deren anwendung bei der diagnostischen bilderzeugung ATE437878T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0502921A FR2883562B1 (fr) 2005-03-24 2005-03-24 Chelates lipophiles et leur utilisation en imagerie
PCT/EP2006/061034 WO2006100305A2 (fr) 2005-03-24 2006-03-24 Chelates métalliques de dérivés macrocycliques polyaminocarboxyliques et leur utilisation en imagerie diagnostique

Publications (1)

Publication Number Publication Date
ATE437878T1 true ATE437878T1 (de) 2009-08-15

Family

ID=35311843

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06725304T ATE437878T1 (de) 2005-03-24 2006-03-24 Metallchelate von makrocyclischen polyaminocarbonsäurederivaten und deren anwendung bei der diagnostischen bilderzeugung

Country Status (7)

Country Link
US (1) US8268810B2 (de)
EP (1) EP1885721B1 (de)
AT (1) ATE437878T1 (de)
DE (1) DE602006008135D1 (de)
ES (1) ES2330140T3 (de)
FR (1) FR2883562B1 (de)
WO (1) WO2006100305A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8926945B2 (en) * 2005-10-07 2015-01-06 Guerbet Compounds comprising a biological target recognizing part, coupled to a signal part capable of complexing gallium
FR2906806B1 (fr) 2006-10-09 2012-12-14 Centre Nat Rech Scient Complexes chelates dendritiques, leurs procedes de fabrication et compositions pharmaceutiques les contenant
FR2914304B1 (fr) 2007-03-28 2012-11-16 Guerbet Sa Composes pour le diagnostic de maladies liees a l'expression de vcam.
FR2914303A1 (fr) 2007-03-28 2008-10-03 Guerbet Sa Composes pour le diagnostic de l'apoptose.
EP2067490A1 (de) * 2007-12-07 2009-06-10 Koninklijke Philips Electronics N.V. Chelatbildnerderivate und diese enthaltende Zusammensetzungen zur Verwendung bei Bildgebungsverfahren
FR2939318B1 (fr) * 2008-12-10 2012-07-13 Guerbet Sa Systeme d'encapsulation pour imagerie cest avec quelate q superieur ou egal a 2
FR2968999B1 (fr) 2010-12-20 2013-01-04 Guerbet Sa Nanoemulsion de chelate pour irm
FR2980364B1 (fr) * 2011-09-26 2018-08-31 Guerbet Nanoemulsions et leur utilisation comme agents de contraste
FR2980365B1 (fr) * 2011-09-26 2016-02-12 Guerbet Sa Nanoemulsions, leur procede de preparation, et leur utilisation comme agent de contraste.
CN104602715A (zh) * 2012-09-07 2015-05-06 伯拉考成像股份公司 用于MRI的包含金属两亲配合物的顺磁性固体脂质纳米颗粒(pSLN)
EP3380484A1 (de) 2015-11-26 2018-10-03 Debreceni Egyetem Neue, auf 6-oxa-3,9,15-triaza-bicyclo[9.3.1]pentadec-a-1(14),11(15),12-trien-derivaten basierende verbindungen und deren anwendung als liganden von essentiellen metallionenbasiertem mrt und 52mn-basierten pet-kontrastmitteln
US10568976B2 (en) 2015-11-26 2020-02-25 Debreceni Egyetem 3,6,9, 15-tetraaza-bicyclo [9.3.1 ]pentadeca-1(14), 11(15), 12-triene based compounds and their application as ligands of essential metal ion based MRI and 52MN based PET contrast agents
EP3380473A1 (de) 2015-11-26 2018-10-03 Debreceni Egyetem Neue 2,1-l-diaza-[3.3](2,6)pyridinophan-verbindungen und deren anwendung als liganden von auf essentiellen metallionen basierenden mrt-kontrastmitteln und 52mn-basierenden pet-kontrastmitteln
US20210236664A1 (en) * 2018-04-25 2021-08-05 The Johns Hopkins University Alpha particle formulations for treatment of solid tumors
WO2020030618A1 (en) 2018-08-06 2020-02-13 Bracco Imaging Spa Gadolinium bearing pcta-based contrast agents
EP4341296A4 (de) * 2021-05-21 2025-07-30 Northstar Medical Tech Llc Urokinase plasminogen aktivator rezeptor-gerichtetes radiopharmazeutikum
CN114105983B (zh) * 2021-11-09 2023-08-11 国科温州研究院(温州生物材料与工程研究所) 手性1,4,7,10-四氮杂-2,6-吡啶环蕃衍生物及其金属螯合物的制备和应用
JP2025541618A (ja) 2022-11-28 2025-12-22 ノバルティス アーゲー Ｐｃｔａ誘導体、そのコンジュゲート及びその使用
CN121666388A (zh) * 2023-09-01 2026-03-13 江苏恒瑞医药股份有限公司 一种大环化合物及其用途
CN121991166A (zh) * 2024-11-05 2026-05-08 成都纽瑞特医疗科技股份有限公司 放射性配体化合物及其用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5154914A (en) 1990-03-12 1992-10-13 Research Corporation Technologies, Inc. Methods of diagnostic image analysis using lipophilic contrast agents
US5242681A (en) 1990-03-12 1993-09-07 Research Corporation Technologies, Inc. Lipophilic contrast agents for diagnostic image analysis
JPH06507904A (ja) 1991-05-23 1994-09-08 イマアーレクス・フアーマシユーチカル・コーポレーシヨン 磁気共鳴画像形成用の油脂可溶化合物
US6875864B2 (en) 1991-08-01 2005-04-05 Bracco International B.V. Aminocarboxylate ligands having substituted aromatic amide moieties
HUT67602A (en) 1991-12-10 1995-04-28 Dow Chemical Co Process for producing bicyclo-polyaza-macrocyclo-carboxylic acid complexes, their conjugates and contrast materials containing them
AU4237493A (en) * 1993-05-06 1994-12-12 Dow Chemical Company, The Bicyclopolyazamacrocyclocarboxylic acid complexes, their conjugates, processes for their preparation, and use as radiopharmaceuticals
US6132764A (en) 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
US5614170A (en) 1994-11-30 1997-03-25 Hemagen/Pfc Paramagnetic complexes of N-alkyl-N-hydroxylamides of organic acids and emulsions containing same for magnetic resonance imaging (MRI)
US5958371A (en) 1995-06-08 1999-09-28 Barnes-Jewish Hospital Site specific binding system, nuclear imaging compositions and methods
US5833948A (en) 1995-06-15 1998-11-10 Bracco Research S.A. Blood-pool imaging composition comprising micelles containing a lipophilic chelating agent and a non-ionic surfactant
IT1283218B1 (it) 1996-03-08 1998-04-16 Bracco Spa Polichelanti, loro complessi con ioni metallici, loro preparazione e loro usi
US5804164A (en) 1996-03-13 1998-09-08 Research Corporation Technologies, Inc. Water-soluble lipophilic contrast agents
FR2794744B1 (fr) 1999-06-09 2001-09-21 Guerbet Sa Complexes metalliques de polyaminoacides bicycliques, leur procede de preparation et leur application en imagerie medicale
US6776977B2 (en) 2001-01-09 2004-08-17 Bristol-Myers Squibb Pharma Company Polypodal chelants for metallopharmaceuticals
US6517814B2 (en) 2001-01-09 2003-02-11 Bristol-Myers Squibb Pharma Company Macrocyclic chelants useful for metallopharmaceuticals
US7179449B2 (en) 2001-01-30 2007-02-20 Barnes-Jewish Hospital Enhanced ultrasound detection with temperature-dependent contrast agents
ITMI20011518A1 (it) 2001-07-17 2003-01-17 Bracco Imaging Spa Leganti azotati multidentati capaci di complessare ioni metallici e loro uso in diagnostica e in terapia
CN100356984C (zh) 2002-01-24 2007-12-26 巴内斯－朱威胥医院 整联蛋白靶向的影像剂
US7279150B2 (en) 2002-01-24 2007-10-09 Barnes-Jewish Hospital Chelating agents with lipophilic carriers
FR2836916B1 (fr) * 2002-03-05 2004-06-11 Guerbet Sa Oligomeres de chelates de gadolinium, leur application comme produits de contraste en imagerie par resonance magnetique et leurs intermediaires de synthese
WO2004087656A1 (de) 2003-04-03 2004-10-14 Schering Aktiengesellschaft Konjugate 2,4-ethano- und 2,4-propano-überbrückter 3,6,9-triaza-nonansäure-3n, 6n, 9,9n-tetraessigsäure- und entsprechender phosphorsäuremethylen-derivate und deren abkömmlinge mit biomolekülen, verfahren zu deren herstellung und deren verwendung zur herstellung
FR2856689A1 (fr) * 2003-06-25 2004-12-31 Guerbet Sa Composes specifiques a forte relaxivite

Also Published As

Publication number Publication date
FR2883562A1 (fr) 2006-09-29
DE602006008135D1 (de) 2009-09-10
US8268810B2 (en) 2012-09-18
WO2006100305A2 (fr) 2006-09-28
FR2883562B1 (fr) 2009-02-27
WO2006100305A3 (fr) 2006-11-09
EP1885721B1 (de) 2009-07-29
US20090214441A1 (en) 2009-08-27
EP1885721A2 (de) 2008-02-13
ES2330140T3 (es) 2009-12-04

Similar Documents

Publication Publication Date Title
DE602006008135D1 (de) Metallchelate von makrocyclischen polyaminocarbonsäurederivaten und deren anwendung bei der diagnostischen bilderzeugung
CY2024007I2 (el) Γλυκοπυρανοζυλο-υποκατεστημενα παραγωγα βενζονιτριλιου, φαρμακευτικες συνθεσεις που περιεχουν τετοιες ενωσεις, η χρηση τους και μεθοδοι παρασκευης τους
ATE539060T1 (de) Styrylpyridinderivate und ihre verwendung zur bindung und abbildung von amyloider plaque
WO2008008797A3 (en) Luminescent 1-hydroxy-2-pyridinone chelates of lanthanides
WO2007077561A3 (en) Compositions and methods for enhancing in-vivo uptake of pharmaceutical agents
WO2006108405A3 (de) Nanopartikel-wirkstoff-konjugate
UY31145A1 (es) Derivado de 17b+ciano-18a-homo-19-nor-androst-4-eno, su uso y medicamento que lo contiene
SG158175A1 (en) Lipid complexes coated with peg and their use
EA200602077A1 (ru) Активируемые частицы, их получение и применение
WO2010138837A3 (en) Nanodiamond particle complexes
CY1113890T1 (el) Φαρμακευτικοι συνδυασμοι που περιεχουν βενζοξαζινες για τη θεραπεια νοσων των αναπνευστικων οδων
WO2009158698A3 (en) Targeted delivery of imaging probes for in vivo cellular imaging
CY1111022T1 (el) Νεοι φαρμακευτικοι συνδυασμοι για τη θεραπεια νοσων των αναπνευστικων οδων
WO2009110984A3 (en) Contrast agents for applications including perfusion imaging
MX2008010070A (es) Uso de compuestos de metales complejos como catalizadores de oxidacion.
WO2007002109A3 (en) Multidentate pyrone-derived chelators for medicinal imaging and chelation
WO2006090389A3 (en) Novel diagnostic markers, especially for in vivo imaging, and assays and methods of use thereof
ECSP088287A (es) Una combinación de compuestos que puede ser utilizada en el tratamiento de enfermedades respiratorias, especialmente enfermedad pulmonar obstructiva crónica (epoc) y asma
ATE361299T1 (de) Oligomere der gadolinium chelate, ihre verwendung als nmr-kontrastmittel und zwischenverbindungen
DE602006015929D1 (de) Doxorubicin-immuntest
EP2402321A3 (de) Chemische Derivate aus Jasmonat, pharmazeutische Zusammensetzungen und Verwendungsverfahren dafür
WO2009032172A3 (en) Platinum compositions as treatment for oct-related cancers
EP2280052A4 (de) Fluoreszierende verbindungen zur diagnose von infektionen, ihre herstellung und verwendungen
UY31146A1 (es) Derivado de 17b-ciano-19-nor-androst-4-eno, su uso y medicamento que lo contiene
WO2006097617A3 (fr) Nouveaux derives dihydropyrimidines et leur utilisation comme agents anti-cancereux

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties